i: Coding

Coding refers to giving particular medical diagnoses or concepts a code that allows them to be sorted within a database. I am most familiar with the ICD-10-AM coding system which is used in Australia. ICD 10 is published by the World Health Organisation and replaced the older ICD 9 system which is still in use in the USA. Another modification is the ICD-10-CM. Some typical codes for ICD 10 might be:

C50.4 - Malignant neoplasm of the upper outer quadrant of the breast (all malignant disease has a C prefix)
D05.1 - Ductal carcinoma in situ of the breast (all in situ disease has a D prefix)
C83.3 - Diffuse large B cell lymphoma
C77.0 - Secondary malignant neoplasm of the lymph nodes of the head and neck (this is a PRIMARY diagnosis of a disease where a PRIMARY cannot be found. It is not used to indicate a neck node recurrence of a known H&N primary, as this is an issue for staging. Note that diagnoses C77-C80 deal with the unknown primary)

There is also a particular oncology coding system known as ICD-O, the latest version of which is ICD-O-3. The deficiency of ICD-O over ICD-10 is that only solid tumour oncology codes are used (C00 - C80), and the codes represent site only. There are no haematology codes, or codes for benign, in situ, or unknown behaviour. The specification requires an additional M code to specify the morphology and behaviour (malignant (3)/borderline & in situ (2)/benign (1)). Grade is not included. From the example above:

C50.4 - M8500/3 (Ductal carcinoma arising from the upper outer quadrant of the breast)
C50.4 - M8500/2 (Ductal carcinoma in situ arising from the upper outer quadrant of the breast)
C77.8 - M9680/3 (Diffuse large B cell lymphoma arising from multiple lymph node sites)
C77.0 - M8070/6 (Squamous cell carcinoma metastatic to lymph nodes of the head and neck)

While ICD-O-3 appears to give better detail regarding the type of cancer as well as the site of cancer and despite the fact that some jurisdictions use it for cancer registries, the use of ICD10 and the ICD10-M codes results in more expressiveness, particularly when the lymphomas are included. It should be noted that extranodal lymphomas pose a problem - Is a Diffuse large B cell lymphoma of the upper outer quadrant of the breast classified as a C83.3 - M9680/3 - Stage IE(breast), or as a C50.4 - M9680/3 - Stage IE. Cancer Registries are not uniform in their management of this instance. Included in this issue is tha obvious lack of consultations with clinicians who are the ones who decide which code to assign. This has occurred because in the past clinicians have no provided these codes. Now that Cancer Registries can poll the Oncology Information Systems of Cancer Centres (as NSW Health does), they can receive the ICD codes for site and morphology directly from the 'horse's mouth'.

The use of the ICD system is subject to 'rules' that have everything to do with governmental/managerial bean counters and little to do with clinical care. The image below demonstrates this problem:

ICD10CMinstruction.jpg

The treatment of a nodal recurrence determines the coding of the nodal recurrence. In my thinking, the nodal recurrence is a recurrence of the original disease, not a new diagnosis. We are blessed (cursed?) with this notion of diagnosis and stage, which the makers of ICD seem to have overlooked.

To further make my point, I offer another instruction and ask you ponder how you would code such a thing. In a patient with a previous cancer, I would add the ICD10 code for the site and morphology and use the date of diagnosis. Unfortunately I can't decipher this.

ICD10CMinstruction2.jpg

My experience is a hybrid of ICD-10 and ICD-O. The diagnosis is coded as per ICD-10, but a subsequent field allows for selection of histological type (as described above). The advantages of this approach is that the coding is as complete as it can be and no more work than satisfying the dictates of ICD-O-3. I understand that the ICD-10-CM alleviates this somewhat as the coding for lymphomas adds an additional digit to specify site (e.g. C83.38 to denote DLBCL arising in multiple lymph node sites).

If you are going to be doing any coding, I would recommend looking at the WHO ICD-10 page which allows for easy searching of all codes. You can find it here.

The coding of various anatomical sites is discussed in the following subtopics.

C00-C14, C30-C32: Head and Neck

C15-C26: Digestive Organs

C33-39: Thoracic Organs

C40-41: Bone and Cartilage

C43-44: Skin

C45-49: Mesothelial and Soft Tissue

C50: Breast

C51-58: Gynaecological

C60-63: Male Genital

C64-68: Urinary Tract

C69: Orbit

C70-72: CNS

C73-75: Endocrine

C76: Ill Defined Sites

C77-79: Metastatic Sites

C80: Unknown Primary Site

C81-96: Haematology

D00-D47: Non Invasive Tumours

Other codes: Non Neoplastic Codes

Syndromes: Codes for cancer syndromes


Links